Overview

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:
0

Participant gender:
All

Summary

The goal of this clinical research study is to evaluate the effectiveness of melatonin for the management of poor appetite and weight loss in advanced cancer patients. The effectiveness of melatonin on weight gain, keeping/gaining of lean muscle mass, improved appetite, and side effects will also be evaluated.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Melatonin

Criteria

Inclusion Criteria:

1. Patients with solid gastrointestinal tumors or lung cancer patients referred to
palliative care and a 5% or more involuntary weight loss within the last 6 months with
anorexia (>3 on visual analog scale such as ESAS)

2. Greater than or equal to 18 years of age

3. Karnofsky score of 40 or higher

4. Patient has the ability to maintain oral food intake during the study period

5. If patients who have persistent anorexia/cachexia and are currently taking Megace,
corticosteroids, non-steroidal anti-inflammatories (NSAID's), or thalidomide, they
should be on the medication at least 2 weeks prior to study inclusion

6. Ability to sign informed consent and understand study procedures

7. Patient can continue all medications including complementary therapies or
antineoplastic therapy while on-study other than melatonin if they have been on stable
dose for at least 2 weeks

8. Negative pregnancy testing in women with child bearing potential defined as not
post-menopausal for 12 months or no previous surgical sterilization.

9. Patients who cannot take Megace because of past history or elevated risk of DVT,
adrenal insufficiency, impotence, hyperglycemia, CHF, menorrhagia, etc.

10. Patients who have persistent anorexia/cachexia after treatment with Megace has failed

Exclusion Criteria:

1. Patients who have dementia or delirium on entry into study as determined by the
palliative care specialist using DSM-IV-criteria

2. Patients who are currently taking melatonin

3. Inability to take oral food during the study period

4. Unstable secondary cachexia caused by nausea, diarrhea, taste abnormalities,
mucositis, constipation, dysphagia, or clinical depression prior to study inclusion.
These symptoms should be resolved or stable for >/= 2 weeks at the time of inclusion
into study as determined by the Palliative Care Specialist.

5. Inability to sign informed consent or understand study procedures

6. Karnofsky score of < 40

7. Patients < 18 years of age

8. Patients with < 3 on ESAS

9. Patients who are on complementary therapies containing melatonin or on medications for
< 2 weeks and not on stable dose

10. Patients who have a cortisol level of unless they are on replacement corticosteroids.

11. Patients with a TSH of /= 10 mcL/mL at baseline will be excluded

12. Pregnant females or females who are lactating/nursing